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ABSTRACT
Objective: A clinical study on etiopathogenesis of Sthaulya and its management with Medohar compound.
Methods: In this study, single and compound drugs are used for the clinical trial. In the present study, total 75 patients of Sthaulya were registered; 
out of which, 15 patients left against medical advice. Remaining 60 patients were treated in three therapeutic groups. For this present study, Medohar 
Vati (Group A), Iesabgol Husk (Group B), and Navaka Guggulu (Group C) have been selected. These drugs have Medohar property. Medohar Vati is 
made up of Charakokt Medohar Dravyas recommended in Sutra sthan (Ch. Su. 21/24). Iesabgol Husk has been selected on the basis of its Medohar 
property narrated by Acharya Priyavritta Sharma in Dravyaguna Vigyan. In Group A, 25 patients treated with Medohar Vati in a dose of 1 g 3 times a 
day, with lukewarm water before meal for 60 days. Whereas in Group B, 13 patients were treated with Iesabgol Husk in a dose of 15 g 2 times a day, 
with lukewarm water before meal for 60 days. Whereas, in Group C, 22 patients were treated with Navaka Guggulu in a dose of 1 g 3 times a day, with 
lukewarm water before meal for 60 days.
Results: On general symptoms, Group A 56.47%, Group B 58.18%, and in Group C 48.46% relief was observed. On associated symptoms, Group A 
44.20%, Group B 47.19%, and in Group C 35.14% relief was observed. On weight and body mass index (BMI), Group A 3.39%, Group B 5.07%, and in 
Group C 2.28% relief was observed. On body circumference, Group A 3.51%, Group B 2.87%, and in Group C 2.72% relief was observed. On skinfold 
thickness, Group A 17.16%, Group B 18.82%, and in Group C 10.63% relief was observed. On walking time and respiratory rate, Group A 17.13%, 
Group B 20.13%, and in Group C 14.84% relief was observed. If we see the overall effect of all three groups in total average improvement, then we 
found that Group A 23.64%, Group B 25.38%, and in Group C 19.01% relief was observed.
Conclusion: On general symptoms, Group A 56.47%, Group B 58.18%, and in Group C 48.46% relief was observed. On associated symptoms, Group A 
44.20%, Group B 47.19%, and in Group C 35.14% relief was observed. On weight and BMI, Group A 3.39%, Group B 5.07%, and in Group C 2.28% 
relief was observed. On body circumference, Group A 3.51%, Group B 2.87%, and in Group C 2.72% relief was observed. On skinfold thickness, Group A 
17.16%, Group B 18.82%, and in Group C 10.63% relief was observed. On walking time and respiratory rate, Group A 17.13%, Group B 20.13%, and in 
Group C 14.84% relief was observed. If we see the overall effect of all three groups in total average improvement, then we found that Group A 23.64%, 
Group B 25.38%, and in Group C 19.01% relief was observed. Thus, in this way, overall comparison of all the parameter showed that effect of Group B 
was better than Group A, but Group A was better than Group C.
Keywords: Sthaulya, Obesity, Medoroga.
INTRODUCTION
Sthaulya the disease may be compared to obesity in modern medicine, 
wherein the lipid metabolism is chiefly altered. Obesity (Sthaulya) is one 
among the major diseases of modern era. In modern era with continuous 
changing lifestyles and environment and changed diet habits, man has 
become the victim of many diseases caused by unwholesome dietary 
habits; the “obesity” is one of them. A recent world health study reports 
that obesity is included among the top 10 selected risks to health. 
Obesity is a blessing of the modern age of machines and materialism. 
It occurs as a result of lack of physical activity with increased intake of 
food. Everybody is busy and living fast and stressful life. High caloric, 
fast food consumption is also increasing. The industrialization, stress 
during the work, dietary habits, lack of exercise, and various varieties 
among the daily diet, e.g., fast food, freezed fruits, increased amount of 
soft drinks and beverages, canned foods result into the clinical entity, 
which we can call as obesity. In the recent years, obesity attracted 
the attention of the medical fraternity. It is the most common and 
adverse nutritional problem in the industrialized world. Moreover, 
now obesity has become a global problem. Recently (January 2009), 
Indian Airlines sacked 9 air hostesses reportedly for overweight. 
Because they were unable to get back into shape and had been declared 
permanently medically unfit. Obesity is such a disease, which provides 
the platform for so many hazards such as hypertension, coronary heart 
disease, diabetes mellitus, osteoarthritis, infertility, and impotency as 
psychological disorders such as stress, anxiety, and depression. These 
indicate the weakening of the various body systems which, in turn, 
affects the physiological equilibrium. Thus, the mortality and morbidity 
rates are more in an obese person. The aim of Ayurveda Shastra is 
to maintain swasthya of swastha purusha and to cure the disease of 
pathological condition of the patient. In other words, Ayurveda guides 
the masses to overcome the diseased condition by preventive methods.
According to modern, obesity is:
•	 An	excessive	deposition	of	adipose	tissue	in	the	body.	Body	weight	
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•	 Body	mass	 index	 (BMI)	>25	kg/m2 (National Institute of Health 
Consensus Conference) [1]. An abnormal growth of adipose tissue 
due to an enlargement of fat cell size or an increase in fat cell number 
or a combination of both.
DEFINITION OF OBESITY
Obesity is a condition, in which there is an excessive amount of body 
fat [2]. According to Dorland, “obesity is an increase in body weight 
beyond the limitation of skeletal and physical requirements as the 
result of excessive accumulation of body fat [3].” Obesity is defined by 
most authorities as occurring when a person weight is at least 10% in 
excess of the normal or required weight [4]. “Parks” has given views as 
obesity may be defined as an abnormal growth of the adipose tissue due 
to an enlargement of fat cell size (hypertrophic obesity) or an increase 
in fat cell number (hyperplastic obesity) or a combination of both [5]. 
Hence, the modern terminology obesity can be used satisfactorily for 
the disease Sthaulya. A body weight 20% or more above desirable 
weight for age, sex, and height is regarded as obese. Obesity has also 
been	defined	as	body	content	>25%	of	total	body	weight	for	male	and	
>30%	for	 female.	Obesity	 can	be	defined	as	an	 “Excessive	deposition	
or distribution of fat in the body.” A recent National Institute of Health 
Consensus	 Conference	 defined	 obesity	 as	 BMI	 >27	 kg/m².	 Now	 a	
days,	obesity	is	defined	at	or	>25	kg/m²	BMI.	In	general,	it	is	a	chronic	
condition defined by an excess amount body fat, but the meaning of 
excess is hard to define. A certain amount of body fat is necessary for 
storing energy, heat insulation, shock absorption, and other functions. 
Obesity is best defined as any degree of excess adiposity that imparts a 
health risk. Visual inspection of a patient can give a subjective but fairly 
accurate estimate of the degree of obesity.
METHODS
In this study, single and compound drugs are used for the clinical trial. 
In the present study, total 75 patients of Sthaulya were registered; out 
of which, 15 patients left against medical advice. Remaining 60 patients 
were treated in three therapeutic groups. For this present study, Medohar 
Vati (Group A), Iesabgol Husk (Group B), and Navaka Guggulu (Group C) 
have been selected. These drugs have Medohar property. Medohar Vati 
is made up of Charakokt Medohar Dravyas [6] recommended in Sutra 
sthan (Ch.Su. 21/24). Iesabgol Husk has been selected on the basis 
of its Medohar property narrated by Acharya Priyavritta Sharma in 
Dravyaguna Vigyan [7]. In Group A, 25 patients treated with Medohar 
Vati in a dose of 1 g 3 times a day, with lukewarm water before meal for 
60 days. Whereas in Group B, 13 patients were treated with Iesabgol 
Husk in a dose of 15 g 2 times a day, with lukewarm water before meal 
for 60 days. Whereas in Group C, 22 patients were treated with Navaka 
Guggulu in a dose of 1 g 3 times a day, with lukewarm water before meal 
for 60 days.
Selection of drugs
For this present study, Medohar Vati (Group A), Iesabgol Husk 
(Group B), and Navaka Guggulu (Group C) have been selected. These 
drugs have Medohar property. Medohar Vati is made up of Charakokt 
Medohar Dravyas [6] recommended in Sutra sthan (Ch. Su. 21/24). 
Iesabgol Husk has been selected on the basis of its Medohar property 
narrated by Acharya Priyavritta Sharma in Dravyaguna Vigyan [7]. 
Navaka Guggulu has been selected on the basis of recommendation by 
the author of Bhaishajya Ratnavali (39/43) [8].
Drug, doses, and duration
Group A: Medohar Vati. Ingrédients of Medohar Vati: (1) Haritaki 1 part, 
(2) Vibhitki 1 part, (3) Aamalaki 1 part, (4) Vidang 1 part, (5) Yavakshar 
1 par, (6) Agnimantha Q. S. (Bark kwath), (7) Madhu Q.S. Doses: Medohar 
Vati 1 g/T.D.S, with lukewarm water before breakfast, lunch, and dinner 
(Nirannakala). Duration: 2 months. Anupan: Lukewarm water.
Group B: Iesabgol Husk. Ingrédients: Iesabgol seed husk. Doses: 
Iesabgol husk 15 g/B.D. Duration: 2 months. Anupan: Lukewarm water.
Group C: Navaka Guggulu. Ingrédients of Navaka Guggulu: (1) Sunthi, 
(2) Marich, (3) Pippali, (4) Chitraka, (5) Haritaki, (6) Bibhitaka, 
(7) Amalaki, (8) Musta, (9) Vidanga, (10) Shudha Guggulu. Duration: 
2 months Anupan: Luke warm water.
Criteria of assessment
These methods are unsuitable for routine use. Thus, indirect methods 
of measuring body fat are more commonly utilized in clinical and field 




Purvarupas of Sthaulya are not mentioned in any of ayurvedic 
texts. According to Charaka, wherever Purvarupa of disease are not 
mentioned, the weak manifestation of Rupa should be considered as 
Purvarupa of the concerned diseases (Ch. Chi. 28/19; Ch. Chi. 11/12). 
Keeping the views of Acharya Charaka in mind, Lakshana of Kapha 
vriddhi such as Alasya, Angashaithilya, Madhurasyata, Atinidra, and 
Atipipasa may be considered as Purvarupa.
“Rupa” of Sthaulya
Disease is known by its interrogation; observation, and inference. Rupa 
serves as an instrument in all these three. On the completion of Dosha-
Dushya Sammurchana, the features of the manifested disease are 
Rupas. Different Acaryas have presented the symptoms of Sthaulya in 
their texts. Sage Charaka has described cardinal or Pratyatma Laksana 
of Sthaulya in Sutra sthan (21/9) as:
 MedoMamsa Ativriddhitva ch chalasphikudarastanah
 Ayathoupachayaanutsahonaroatisthulauchayate - (Charaka Su.21/9)
Which means the inordinate increase of fat and flesh is disfigured by 
pendulous buttocks, abdomen, and breast and that increased bulk 
reduces the corresponding increase in energy. So, the person has less 
enthusiasm in his physical activity. Charaka has enlisted the following 








Besides above-mentioned cardinal symptoms, eight disabilities are 
the most prominent clinical features of Sthaulya narrated by Acharya 
Charaka (Su. 21/4), i.e.,
1. Ayushohrasa (diminution of life span),
2. Javoparodha (lack of agility),
3. Krcchra Vyavaya (difficulty in sexual act),
4. Daurbalya (debility),
5. Daurgandhya (Foul smelling of body),
6. Swedabadha (Distressful sweating),
7. Ksudha Atimatra (Excessive hunger),
8. Pipasa Atiyoga (excessive thirst).
Susruta (Su. Su. 15/32) and Vagbhata (AS. Su 24/23-26) also described 
these.
Symptoms
All the symptoms of Sthaulya described in various ayurvedic texts are 
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Visual inspection of a patient can give a subjective but fairly accurate 
estimate of the degree of obesity. “If a person looks fat, the person is 
fat [9].”
Obesity can be assessed in several ways. The direct methods of 
measuring body fat include underwater weighing (densitometry), 
estimation of total body water, estimation of total body potassium, and 
estimation of fat cell mass by isotope dilution method. Both “computed 
tomography” and “nuclear magnetic resonance imaging” can be used to 














Height inches 2( )
According to the BMI, patients can be divided into different degrees of 
obesity as below:
BMI classification:
1. Overweight: 25-29.9 kg/m2
2. Obesity (Class I): 30-34.9 kg/m2







1. Grade 0 = <25
2. Grade 1 = 25-29.9
3. Grade 2 = 30-40
4.	 Grade	3	=	>40.
Correlation between ayurved and modern classification based on BMI:
Health risks increase as BMI increases above 25. The National Institute 
of Health Consensus Panel on obesity agreed with the definition and 
concluded that a 20% increase in relative weight for young adults 
constitutes a health risk, by the use of these criteria, 20-30% of adult 
men, and 30-40% of adult women are obese, with the highest rates 
among the poor and minority groups.
The qualifier “morbid” is applied to the condition when the amount of 
overweight is 49.5 kg or more or when the patient is more than twice 
ideal weight.
The use of height weight tables based on averages to assess the severity 
of a given patient over weight does not take into account the distribution 
of body fat, which as will be explained below, influences the morbidity 
from excess weight, as well as other important factors such as age and 
social, economic, and ethnic status.
A simple but fairly good index of obesity consists in grasping the skin on 
the side of the body just below the ribs between the thumb and index 
finger. If the thickness of the fold exceeds one inch, a person is obese. 
Assessment of skinfold thickness over various areas of body together 
with height, weight, and age can be used to assess the degree of adiposity.
More precise assessment of obesity can be made with measurements of 
body density or with isotopic dilution methods, but these are unsuitable 
for routine use.
To estimate ideal body weight, simple way is assuming a base line of 
49.5 kg (110 lb) for 150 cm (5 ft) individual and adding 2 kg (5 lb) for 
each 2.5 cm (1 inch) over 150 cm. Plus 2 kg for a medium frame or 
4.5 kg (10 lb) for heavy frame.
The normal amount of body fat (expressed as percentage of body fat) is 
between 25% and 30% in women and 18-23% in men. Women with over 
30% body fat and men with over 25% body fat are considered obese.
Effect on biochemical parameters
During the study, maximum biochemical parameters before and after 
treatment were found within normal limit. In all three groups, no 
apparent changes were observed in biochemical investigations because 
it may be due to the short duration of the thesis work
OBSERVATION AND RESULT
Observation is based on 75 registered patients of Sthaulya for study 
(Tables 1-19).
Adverse drug reaction (ADR)
No ADRs attributable to the trial drugs observed during the study.
Effect on functional assessment
Chief complaints
Around 100% patient shows that were having Bharavrridhi, 
whereas 94.67% patients were having Daurgandhyata, 90.67% 
Ayaseswaskastata, 98.67% Angagauravata, 97.33% Angachalatva, again 
97.33% Atikshudha, 76% Atinidra, and 20% patients were having 
complain of Atipipasa.
In obese person, fatty mass is increased and lean body mass is decreased 
as fat is bulkier than muscle. 1 kg of fat requires approximately 
1.5 times more space than 1 kg of muscles. Therefore, Bharavriddhi 
and Angachalatva take place. Moreover, due to obstruction (Avarna) 
of Vyana Vayu by Meda, it gets vitiated. Thus, it could not transport 
nutrient to the next Dhatu. Hence, it causes Dhatu Kshaya, which results 
into Daurbalya and Kshudra Shwasa. Modern science has also accepted 
obesity as one of the causes for Dyspnea.
Although Vyavayakashtata is an important symptom, there is no 
reporting found of this ailment among these patients? My all patients 
Type BMI
Heena Sthaulya (overweight) 25-34.99 kg/m2
Madhyam Sthaulya (obesity Grade 1st and 2nd) 30-30.99 kg/m2
AtiSthaulya (severe or morbid obese) >40	kg/m2
Assessment criteria of therapy
In this part, percentage improvement was taken to assess the overall 
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Table 1: Improvement difference between groups
Difference between groups For Group A For Group B For Group C
n=25 n=13 n=22
D.F.=24 D.F.=12 D.F.=21
Symptoms % of improvement % of improvement % of improvement
Daurgandhya 55.17 62.50 54.90
Ayase-shwas 55.17 61.90 47.73
Angagauravata 45.28 36.00 27.27
Atikshudha 63.49 65.96 51.43
Atipipasa 73.68 50.00 60.00
Chalasphika 31.43 18.18 10.71
Chalauadara 31.88 12.50 15.00
Chalastana 30.30 34.62 10.71
Utsahahani 64.62 65.38 56.00
Daurbalya 62.86 53.13 50.88
Nidraadhikya 71.79 69.23 65.71
Snigdhagatrata 55.38 52.17 45.10
Sandhishool 60.98 68.42 54.55
Atimutrata 88.89 100.00 71.43
Angashaithilya 2.78 13.64 1.79
Table 2: Effect on weight and BMI by Medohar Vati
Weight and BMI For Group A For Group B For Group C
Symptoms % of improvement % of improvement % of improvement
Weight 3.37 4.93 2.16
BMI 3.37 5.01 2.21
Table 3: Effect on circumference by Medohar Vati 
Circumference (cm) For Group A For Group B For Group C
Symptoms % of improvement % of improvement % of improvement
Chest 3.23 2.44 2.73
Abdomen 3.65 2.96 3.47
Hip 3.40 2.41 2.30
Thigh 5.61 4.58 2.52
Leg 3.37 2.86 2.44
Arm 1.25 3.42 3.91
Forearm 1.28 1.57 1.16
Table 4: Effect on skinfold thickness by Medohar Vati
Symptoms For Group A For Group B For Group C
% of improvement % of improvement % of improvement
Skinfold thickness (cm)
Biceps 17.97 25.62 12.12
Triceps 15.43 12.19 9.40
Walking time in seconds and respiratory rate/m
Walking time 18.05 23.44 12.12
Respiration rate 16.42 16.71 9.40
are below 40 kg/m2 BMI. That might be the reason for this. Because 
above 40 kg/m2, BMI is my exclusion criteria.
Effect of therapies
The sample of 60 patients was selected and subdivided according to 
drug availability into three groups, 25 patients in Group A, 13 patients 
in Group B, and 22 patients in Group C.
In Group A, Medohar Vati; in Group B, Iesabgol Husk; and in Group C, 
Navaka Guggulu tab were administered. Medohar Vati and Navaka 
Guggulu were administered in the dose of 1 g thrice a day for 60 days 
with lukewarm water before meal, whereas, in Group B, 15 g Iesabgol 
Husk 2 times with lukewarm water before meal was administered in 
the same duration (60 days).
Treatment was observed according to the plan of study. The results 
were derived after execution of statistical techniques. The effect of 
therapy has been presented as follow.
Effect on symptomatology
In Group A, 55.17% in Daurgandhya and Ayase-shwas, 45.28% 
Angagauravata, 63.49% Atikshudha, 73.68% Atipipasa, 31.43% 
Chalasphika, 31.88% Chalauadara, 30.30% Chalastana, 64.62% 
Utsahahani,	 62.86%	 Daurbalya,	 71.79%	 Nidraadhikya,	 55.38%	
5
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Table 5: Medohar Vati
Effect of drug For Group A t value
Group A n=25 0.05 0.01 0.001
D.F.=24 2.06 2.80 3.76
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Daurgandhya 2.32 1.04 55.17 0.46 0.09 13.97 <0.001
Ayaseswas 2.32 1.04 55.17 0.46 0.09 13.97 <0.001
Angagauravata 2.12 1.16 45.28 0.61 0.12 7.86 <0.001
Atikshudha 2.52 0.92 63.49 0.76 0.15 10.47 <0.001
Atipipasa 0.76 0.20 73.68 0.65 0.13 4.30 <0.001
Chalasphika 2.80 1.92 31.43 0.67 0.13 6.61 <0.001
Chalauadara 2.76 1.88 31.88 0.73 0.15 6.06 <0.001
Chalastana 2.64 1.84 30.30 0.65 0.13 6.20 <0.001
Utsahahani 2.60 0.92 64.62 0.56 0.11 15.09 <0.001
Daurbalya 2.80 1.04 62.86 0.52 0.10 16.83 <0.001
Nidraadhikya 1.56 0.44 71.79 0.73 0.15 7.72 <0.001
Snigdhagatrata 2.60 1.16 55.38 0.58 0.12 12.35 <0.001
Sandhishool 1.64 0.64 60.98 0.58 0.12 8.66 <0.001
Atimutrata 0.36 0.04 88.89 0.48 0.10 3.36 <0.01
Angashaithilya 2.84 2.80 2.78 0.35 0.07 0.57 >0.05
SD: Standard deviation, SE: Standard error
Table 6: Effect on weight and BMI by Medohar Vati
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Weight 80.23 77.53 3.37 1.38 0.28 9.79 <0.001
BMI 31.41 30.35 3.37 0.53 0.11 9.97 <0.001
BMI: Body mass index, SD: Standard deviation, SE: Standard error
Table 7: Effect on circumference by Medohar Vati
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Chest 102.68 99.36 3.23 1.49 0.30 11.12 >0.001
Abdomen 106.24 102.36 3.65 2.32 0.46 8.38 >0.001
Hip 114.00 110.12 3.40 1.59 0.32 12.20 >0.001
Thigh 62.08 58.60 5.61 2.82 0.56 6.18 >0.001
Leg 39.76 38.42 3.37 1.36 0.27 4.93 >0.001
Arm 32.12 31.72 1.25 0.50 0.10 4.00 >0.001
Forearm 26.58 26.24 1.28 1.18 0.24 1.44 <0.05
SD: Standard deviation, SE: Standard error
Table 8: Effect on skinfold thickness (cm) by Medohar Vati
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Biceps 2.40 1.97 17.97 0.31 0.06 7.08 >0.001
Triceps 2.85 2.41 15.43 0.21 0.04 10.28 >0.001
SD: Standard deviation, SE: Standard error
Table 9: Effect on walking time in seconds and respiratory rate/m by Medohar Vati
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Walking time 27.04 22.16 18.05 1.83 0.37 13.31 <0.001
Respiration rate 24.12 20.16 16.42 1.51 0.30 13.08 <0.001
SD: Standard deviation, SE: Standard error
6
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Table 10: Iesabgol Husk
Effect of drug For Group B t value
Group B n=13 0.05 0.01 0.001
D.F.=12 2.179 3.06 4.32
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Daurgandhya 1.23 0.46 62.50 0.60 0.17 4.63 <0.001
Ayaseswas 1.62 0.62 61.90 0.58 0.16 6.24 <0.001
Angagauravata 1.92 1.23 36.00 0.48 0.13 5.20 <0.001
Atikshudha 3.62 1.23 65.96 0.51 0.14 16.98 <0.001
Atipipasa 1.23 0.62 50.00 0.77 0.21 2.89 >0.01
Chalasphika 1.69 1.38 18.18 0.48 0.13 2.31 >0.01
Chalauadara 1.85 1.62 12.50 0.44 0.12 1.90 >0.05
Chalastana 2.00 1.31 34.62 0.75 0.21 3.32 <0.01
Utsahahani 2.00 0.69 65.38 0.48 0.13 9.81 <0.001
Daurbalya 2.46 1.15 53.13 0.48 0.13 9.81 <0.001
Nidraadhikya 1.00 0.31 69.23 0.63 0.17 3.96 <0.01
Snigdhagatrata 1.77 0.85 52.17 1.04 0.29 3.21 <0.01
Sandhishool 1.46 0.54 68.42 0.82 0.23 4.42 <0.001
Atimutrata 0.31 0.00 100.00 0.48 0.13 2.31 >0.01
Angashaithilya 3 3 13.64 0.44 0.12 1.90 >0.05
SD: Standard deviation, SE: Standard error
Table 11: Effect on weight and BMI by Iesabgol Husk
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Weight 76.25 72.49 4.93 1.80 0.50 7.54 <0.001
BMI 30.55 29.02 5.01 0.77 0.21 7.13 <0.001
BMI: Body mass index, SD: Standard deviation, SE: Standard error
Table 12: Effect on circumference by Iesabgol Husk
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Chest 101.08 98.62 2.44 1.66 0.46 5.33 <0.001
Abdomen 97.42 94.54 2.96 2.89 0.80 3.60 <0.01
Hip 111.69 109.00 2.41 1.97 0.55 4.92 <0.001
Thigh 57.08 54.46 4.58 2.53 0.70 3.72 <0.01
Leg 38.96 37.85 2.86 1.08 0.30 3.71 <0.01
Arm 31.46 30.38 3.42 1.38 0.38 2.81 >0.01
Forearm 26.88 26.46 1.57 0.49 0.14 3.09 <0.01
SD: Standard deviation, SE: Standard error
Table 13: Effect on skinfold thickness (cm) by Iesabgol Husk
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Biceps 2.16 1.61 25.62 0.36 0.10 5.55 <0.001
Triceps 2.46 2.16 12.19 0.16 0.04 6.84 <0.001
SD: Standard deviation, SE: Standard error
Table 14: Effect on walking time in seconds and respiration rate/m by Iesabgol Husk
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Walking time 30.85 23.62 23.44 3.22 0.89 8.10 <0.001
Respiration rate 28.54 23.77 16.71 2.24 0.62 7.67 <0.001
SD: Standard deviation, SE: Standard error
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Table 15: Navaka Guggulu
Effect of drug For Group C t value
Group C n=22 0.05 0.01 0.001
D.F.=21 2.08 2.83 3.12
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Daurgandhya 2.32 1.05 54.90 0.55 0.12 10.84 <0.001
Ayaseswas 2.00 1.05 47.73 0.58 0.12 7.78 <0.001
Angagauravata 2.00 1.45 27.27 0.51 0.11 5.02 <0.001
Atikshudha 3.18 1.55 51.43 0.90 0.19 8.51 <0.001
Atipipasa 0.91 0.36 60.00 0.51 0.11 5.02 <0.001
Chalasphika 2.55 2.27 10.71 0.46 0.10 2.81 >0.01
Chalauadara 2.73 2.32 15.00 0.50 0.11 3.81 <0.001
Chalastana 2.55 2.27 10.71 0.46 0.10 2.81 >0.01
Utsahahani 2.27 1.00 56.00 0.55 0.12 10.84 <0.001
Daurbalya 2.59 1.27 50.88 0.65 0.14 9.57 <0.001
Nidraadhikya 1.59 0.55 65.71 0.58 0.12 8.52 <0.001
Snigdhagatrata 2.32 1.27 45.10 0.72 0.15 6.79 <0.001
Sandhishool 1.50 0.68 54.55 0.59 0.13 6.52 <0.001
Atimutrata 0.32 0.09 71.43 0.43 0.09 2.49 >0.01
Angashaithilya 2.55 2.50 1.79 0.21 0.05 1.00 >0.05
SD: Standard deviation, SE: Standard error
Table 16: Effect on weight and BMI by Navaka Guggulu
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Weight 78.64 76.94 2.16 1.18 0.25 6.74 <0.001
BMI 31.89 31.19 2.21 0.50 0.11 6.67 <0.001
BMI: Body mass index, SD: Standard deviation, SE: Standard error
Table 17: Effect on circumference by Navaka Guggulu
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Chest 101.45 98.68 2.73 1.34 0.29 9.69 <0.001
Abdomen 106.00 102.32 3.47 4.43 0.95 3.90 <0.001
Hip 114.86 112.23 2.30 1.62 0.35 7.63 <0.001
Thigh 61.36 59.82 2.52 1.84 0.39 3.93 <0.001
Leg 41.00 40.00 2.44 1.07 0.23 4.39 <0.001
Arm 32.55 31.27 3.91 1.16 0.25 5.14 <0.001
Forearm 27.34 27.02 1.16 0.72 0.15 2.08 >0.01
SD: Standard deviation, SE: Standard error
Table 18: Effect on skinfold thickness (cm) by Navaka Guggulu
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Biceps 2.36 2.08 12.12 0.32 0.07 4.14 <0.001
Triceps 2.95 2.67 9.40 0.23 0.05 5.63 <0.001
SD: Standard deviation, SE: Standard error
Table 19: Effect on walking time in seconds and respiration rate/m by Navaka Guggulu
Symptoms Mean % of improvement SD SE “t” p
B.T. A.T.
Walking time 26.41 21.91 17.04 2.86 0.61 7.39 <0.001
Respiration rate 25.64 22.32 12.94 1.91 0.41 8.14 <0.001
SD: Standard deviation, SE: Standard error
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Group A: Individual symptom‑wise improvement of patients
Group A Improvement in percentage










Time and respiratory 
rate
Total Over all
1 68.75 63.64 5.21 2.66 6.25 16.33 162.84 27.14
2 62.50 54.84 2.41 3.70 14.58 13.56 151.60 25.27
3 69.23 47.62 3.71 4.44 25.00 21.67 171.67 28.61
4 57.14 46.67 0.92 2.32 16.67 17.74 141.46 23.58
5 62.50 47.06 2.64 2.80 17.78 15.69 148.47 24.74
6 50.00 28.57 2.31 2.59 8.82 25.00 117.30 19.55
7 40.00 37.50 3.46 2.64 13.56 17.02 114.18 19.03
8 50.00 33.33 1.54 2.10 8.11 25.00 120.08 20.01
9 71.43 56.25 1.26 2.34 13.79 15.22 160.29 26.71
10 58.33 37.50 5.69 4.26 17.81 17.31 140.90 23.48
11 53.85 48.28 4.88 2.45 7.69 20.69 137.83 22.97
12 44.44 47.37 7.79 4.56 28.57 22.22 154.95 25.83
13 50.00 36.00 2.10 2.42 25.49 16.00 132.01 22.00
14 55.56 30.43 1.75 3.38 11.76 11.54 114.42 19.07
15 60.00 40.91 2.00 5.85 38.18 14.29 161.23 26.87
16 60.00 39.13 2.87 4.89 28.85 18.87 154.60 25.77
17 50.00 66.67 4.37 3.13 30.00 15.91 170.07 28.34
18 55.56 34.62 1.89 3.08 15.38 14.29 124.81 20.80
19 61.54 42.86 3.35 4.88 14.75 13.73 141.10 23.52
20 62.50 50.00 3.86 4.83 18.60 15.56 155.35 25.89
21 50.00 46.67 6.04 4.45 25.00 17.78 149.93 24.99
22 58.33 41.67 2.83 3.35 15.09 14.00 135.28 22.55
23 50.00 40.00 3.49 3.57 13.21 17.31 127.58 21.26
24 60.00 41.67 5.01 3.64 6.90 15.91 133.12 22.19
25 50.00 45.83 3.51 3.51 7.02 15.56 125.42 20.90
















BMI: Body mass index
Group B: Individual symptom‑wise improvement of patients
Group B Improvement in percentage














1 50.00 38.89 7.94 2.40 27.91 20.00 147.14 24.52
2 53.85 43.75 6.25 1.74 12.82 16.13 134.53 22.42
3 60.00 53.85 2.38 1.88 15.56 22.73 156.38 26.06
4 54.55 44.44 3.71 3.37 29.27 19.67 155.00 25.83
5 66.67 55.56 8.57 4.83 28.57 27.27 191.46 31.91
6 62.50 38.46 5.73 5.08 14.63 22.81 149.22 24.87
7 44.44 34.78 1.13 1.38 3.92 15.52 101.18 16.86
8 33.33 40.00 2.67 3.28 18.52 19.12 116.92 19.49
9 71.43 71.43 5.75 2.13 32.43 19.64 202.81 33.80
10 70.00 75.00 4.61 1.18 20.00 24.00 194.79 32.46
11 75.00 47.62 4.21 3.90 6.52 13.73 150.97 25.16
12 54.55 41.67 10.06 3.55 24.19 23.08 157.09 26.18
13 60.00 28.00 2.97 2.60 10.34 18.00 121.91 20.32
















BMI: Body mass index
Snigdhagatrata, 60.98% Sandhishool, 88.89% Atimutrata, and 2.78% 
relief were observed in Angashaithilya.
Whereas in Group B, 62.50% in Daurgandhya, 61.90% in Ayase-
shwas, 36.00% Angagauravata, 65.96% Atikshudha, 50.00% Atipipasa, 
18.18% Chalasphika, 12.50% Chalauadara, 34.62% Chalastana, 
65.38%	Utsahahani,	53.13%	Daurbalya,	69.23%	Nidraadhikya,	52.17%	
Snigdhagatrata, 68.42% Sandhishool, 100% Atimutrata, and 13.64% 
relief was observed in Angashaithilya.
Whereas In Group C, 54.90% in Daurgandhya, 47.73% in Ayase-
shwas, 27.27% Angagauravata, 51.43% Atikshudha, 60.00 Atipipasa, 
10.71% Chalasphika, 15.00% Chalauadara, 10.71% Chalastana, 
56.00%	Utsahahani,	50.88%	Daurbalya,	65.71%	Nidraadhikya,	45.10%	
Snigdhagatrata, 54.55% Sandhishool, 71.43% Atimutrata, and 1.79% 
relief was observed in Angashaithilya.
DISCUSSION
Discussion is a process of re-examining oneself. It forms a base for 
conclusion. This is the most important part of any research work. 
According to ancient research, methodology before establishing 
any	 theory,	 Upanayana	 (Discussion)	 is	 the	 prior	 step	 to	 Nigamana	
(conclusion). Discussion is nothing but the logical reasoning 
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of observations. It is a bridge which connects the findings with 
conclusions. Hence, the discussion is very much crucial part of any 
scientific research. The title of study was:
 Sthaulya has been mentioned by Acharya Charaka in Ashtaunindita 
Adhyaya (Charaka Sutra. 21). It means that it is a well-recognized 
disease since the Samhita period [10]. Madhavakara has described 
Medoroga as an individual entity in 34th chapter of Madhava-nidana. 
Medoroga Medosvina, Atisthula, and Sthula are synonymous to 
Sthaulya [11].
In allopathic literature, it is considered as a metabolic disorder named 
as obesity.
Sthaulya or obesity is a burning problem in the world. It is a dreadful 
disease with its hazardous complications such as Hyperlipidemia, 
Atherosclerosis Degenerative Heart Disease, and Diabetes Mellitus. 
These are major causes for mortality and morbidity, not only in western 
countries but also in India [12] (World Health Report – 2002).
Now a day, Obesity is emerging as an important health problem in India. 
The Nutrition Foundation of India study showed that 32.3% of middle-
class male and 50% of middle-class female in Delhi were obese [13] 
(API Textbook of medicine, 7th Edition).
Sushruta has narrated the etiopathogenesis of Sthaulya Roga on the 
basis of an endogenous entity being caused due to “Dhatvagni Mandya” 
(Sushruta Samhita, Sutra 15) [14]. In Sthaulya, Tikshnagni occurs. As per 
the references of Sushruta and further clarified by Dalhana, it is more 
logical to accept that after passing, Rakta and Mamsa Dhatu from Rasa 
excessive Medo Dhatu is produced. Jatharagni is found to be excessive, but 
Medodhatvagni is found to be in Manda condition. It is due to Avarana of 
Vayu in Koshtha. Therefore, person indulges in more food consumption, 
which produces excessive Meda and this vitiated cycle goes on. Due to 
obstruction by Meda, Vyana Vayu cannot transport nutrient to other 
Dhatu,	so	Medadhatu	increases	and	Uttardhatu	decreases.
Medohar Vati
Haritaki, Bibhitaki, Vidanga, Yavakshar, Agnimantha, and Madhu have 
Tikshna,	Laghu,	Gunas,	and	Ushna	Veerya,	which	helps	in	the	clearing	
the obstruction in the channels.
These Tikta drugs possess the Lekhana, Karshana, and Meda-Kleda 
Upashoshana	 properties.	 Bibhitaki	 has	 Chhedan	 property;	 Yavakshar	
has lekhan property which helped in curing the various symptoms of 
Medoroga.	Medohar	Vati	has	katu-ras	and	Ushna-veerya-drvayas,	which	
act on kapha and vayu to break the samprapti of Sthaulya.
In pathogenesis, Avarna of Vata is there. Most of the drugs (5 drugs) 
having	Ushna	Veerya	which	is	effective	against	Vata.
Iesabgol Husk
It has sheet veerya property, and it acts on teekshna-agni to suppress 
increased appetite to reduce calorie intake. It also acts on vitiated 
Pachak–Pitta and normalizes the state of Agni.
It decreases serum cholesterol through proper excretion of bile acids. 
It is also beneficial in appetite and helps in weight control through 
its ability to lower the rate of glucose absorption and bulk-forming 
properties which may enhance the feeling of satiety.
It is well-studied lipid-lowering agent with generally modest reductions 
seen in blood levels of total cholesterol and low-density lipoprotein 
(bad cholesterol).
Navaka Guggulu
In Navaka Guggulu, maximum ingredients have Laghu, Ruksha Guna, 
Katu	 Rasa,	 Ushna	 Virya,	 Katu	 Vipaka,	 and	 Vata-Kapha-shamaka	
properties. Therefore, it is effective to control Sthaulya.
Acharya Shri Govind Das has mentioned “Navaka Guggulu” in Medoroga 
Chikitsa (Bhaishajya Ratnawali 39/43).
Rasapanchaka is very well indicated in Kapha predominant pathologies 
[Cha. Su. 21/23]. Due to this property, it breaks the Samprapti of Sthulya.
As it is Dipana and Pachana, it can do very well in certain Vata-Kapha 
condition like Sthaulya. It has efficacy to correct the function of 
Medodhatvagnimandya.
Iesabgol Husk has sheet veerya property, and it acts on teekshna-agni 
to suppress increased appetite to reduce calorie intake. It also acts on 
Group C: Individual symptom‑wise improvement of patients
Group C Improvement in percentage










Walking time and 
respiratory rate
Total Over all
1 54.55 71.43 2.01 2.74 3.33 11.90 145.96 24.33
2 22.22 17.39 1.70 3.30 14.29 6.78 65.67 10.95
3 60.00 28.57 4.38 3.87 15.79 19.64 132.26 22.04
4 71.43 40.00 5.68 2.81 23.40 18.52 161.84 26.97
5 66.67 83.33 3.30 4.16 13.89 32.00 203.35 33.89
6 54.55 35.29 4.09 2.91 13.24 21.15 131.23 21.87
7 44.44 33.33 4.91 2.44 21.15 18.37 124.65 20.78
8 42.86 27.59 1.44 1.82 18.46 22.03 114.20 19.03
9 37.50 28.57 −1.01 −0.20 4.76 10.00 79.62 13.27
10 38.46 30.77 2.03 2.55 6.45 15.79 96.05 16.01
11 63.64 41.67 2.36 2.53 9.52 21.57 141.28 23.55
12 66.67 56.25 1.58 2.78 9.76 20.00 157.03 26.17
13 57.14 31.58 1.18 1.31 8.70 4.88 104.78 17.46
14 60.00 22.58 0.52 1.67 0.00 11.29 96.06 16.01
15 63.64 32.00 1.44 4.55 19.23 15.38 136.24 22.71
16 35.71 33.33 1.41 7.40 20.00 24.19 122.05 20.34
17 21.43 16.67 −0.84 1.57 −11.67 7.69 34.85 5.81
18 50.00 37.50 3.55 2.45 17.39 16.33 127.22 21.20
19 41.67 22.73 3.02 3.08 6.25 3.51 80.25 13.38
20 37.50 29.41 2.55 2.54 10.71 6.67 89.38 14.90
21 38.46 26.09 1.32 2.30 9.21 12.50 89.88 14.98
22 37.50 26.92 3.48 1.30 0.00 6.25 75.45 12.57
















BMI: Body mass index
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vitiated Pachak–Pitta and normalizes the state of Agni. It is also beneficial 
in weight control through its ability to lower the rate of glucose absorption 
and bulk-forming properties which may enhance the feeling of satiety.
Navaka Guggulu encounters Vata and Kapha Dosha by virtue of its Katu 
Rasa	dominance	and	Ushna	Virya.	Vatahara	action	is	also	achieved	by	
Laghu and Snigdha property.
Effect on dushya
Meda and Kleda are the chief culprits in Sthaulya. Katu Rasa performs 
Medo-kledo-upashoshana	action.	Ushna	Virya	also	helps	in	Kleda	and	
Medavilayana action.
Due to katu Rasa, all the involved channels are dilated. Katu Rasa and 
Ushna	Virya	acts	over	Medovaha	and	Mamsavaha	Srotodushti.
Medohar Vati and Navaka Guggulu both act on above principle.
Iesabgol Husk has Medohar and Mutral properties. It makes sroto-
vishodhan and removes toxic substances from the gut.
Effect on body weight
Medohar Vati provided 3.37% improvement in reduction of body 
Weight.	 It	 may	 be	 due	 its	 Ushna	 dravyas	 dominancy	 and	 Lekhan	
property of the drug.
However, Iesabgol Husk provided 4.93% reduction. It may be due to 
its Pitta-shamaka property which acts on vitiated Pachak–Pitta and 
normalize the state of Agni.
Navaka Guggulu gives only 2.16% Weight reduction which is less than 
other	 two	drugs.	 It	may	also	 act	 on	 the	base	of	 its	Katu	Rasa,	Ushna	
Virya, and Vata–Kapha-shamaka properties.
Effect of therapy on symptoms
Medohar Vati shows the better result on Daurbalya (62.86), 
Nidraadhikya (71.79), and Snigdhagatrata (55.38).
However, Iesabgol Husk shows the better result on atikshudha, 
i.e., 65.96%. Which may be due to its bulk-forming properties, this 
enhances the feeling of fullness and gives satiety to the patient.
CONCLUSION
Effect on body weight
In Group A, weight of patients was reduced to 3.37%. In Group B, weight 
reduction is 4.93%, whereas in Group C, Weight reduction is only 
2.16%. In comparative study, Group B (Iesabgol Husk) gives a better 
result than Group A and Group C. Whereas Group A drug (Medohar Vati) 
is comparatively better than Group C (Navaka Guggulu).
Effect on body circumference
In Group A, chest 3.23%, abdomen 3.65%, hip 3.40%, thigh 5.61%, leg 
3.37%, arm 1.25%, and forearm 1.28% relief was observed. Whereas 
in Group B, chest 2.44%, abdomen 2.96%, Hip 2.41%, thigh 4.58%, leg 
2.86%, arm 3.42%, and forearm 1.57% relief was observed. Whereas 
in Group C, chest 2.73%, abdomen 3.47%, hip 2.30%, thigh 2.52%, leg 
2.44%, arm 3.91%, and forearm 1.16% relief was observed.
Group and symptom‑wise improvement











Walking time and 
respiratory rate
Over all
Group A 56.47 44.20 3.39 3.51 17.16 17.13 23.64
Group B 58.18 47.19 5.07 2.87 18.82 20.13 25.38
Group C 48.46 35.14 2.28 2.72 10.63 14.84 19.01
Group‑wise overall effect
Effect Range (%) Group A Group B Group C Total number of patients
Unchanged 0-10 0 0 1 1
Mild improved 10-25 16 6 18 40
Moderate improved 25-50 9 7 3 19
Mark. improved 50-75 0 0 0 0
Complete remission 75-100 0 0 0 0
Total patient 25 13 22 60
Number of patients in group‑wise improvement
Effect Range (%) Group A ‑ Number 
of patients
Group B ‑ Number 
of patients




Unchanged 0-10 0 0 1 1
Mild improved 10-25 16 6 18 40
Moderate improved 25-50 9 7 3 19
Marked improved 50-75 0 0 0 0
Complete remission 75-100 0 0 0 0
Total patients (n) 25 13 22 60
Percentage of patients in group‑wise improvement
Result Range Group A ‑ Percentage of patient Group B ‑ Percentage of patient Group C ‑ Percentage of patient
Unchanged 0-10 0 0 4.55
Mild improved 10-25 64 46.15 81.82
Moderate improved 25-50 36 53.85 13.64
Marked improved 50-75 0 0 0
Complete remission 75-100 0 0 0
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Effect on skinfold thickness
In Group A, biceps 17.97% and triceps 15.43% relief was observed. 
Whereas in Group B, biceps 25.62% and triceps 12.19% relief was 
observed. Whereas in Group C, biceps 12.12% and triceps 9.40% relief 
was observed.
Effect on walking time and respiration rate
In Group A, walking time 18.05% and respiration rate 16.42% relief was 
observed. Whereas in Group B, walking time 23.44% and respiration 
rate 16.71% relief was observed. Whereas in Group C, walking time 
12.12% and respiration rate 9.40% relief was observed.
Overall effect of therapies
Group-wise improvement
On general symptoms, Group A 56.47%, Group B 58.18%, and in Group C 
48.46% relief was observed. On associated symptoms, Group A 44.20%, 
Group B 47.19%, and in Group C 35.14% relief was observed. On weight 
and BMI Group, A 3.39%, Group B 5.07%, and in Group C 2.28% relief 
was observed. On body circumference, Group A 3.51%, Group B 2.87%, 
and in Group C 2.72% relief was observed. On skinfold thickness, 
Group A 17.16%, Group B 18.82%, and in Group C 10.63% relief was 
observed. On walking time and respiratory rate, Group A 17.13%, 
Group B 20.13%, and in Group C 14.84% relief was observed. If we 
see the overall effect of all three groups in total average improvement, 
then we found that Group A 23.64%, Group B 25.38%, and in Group C 
19.01% relief was observed. Thus, in this way, overall comparison of all 
the parameter showed that effect of Group B was better than Group A. 
However, Group A was better than Group C.
Total effect of therapy
Overall percentage of improvement was calculated on the average of 
total improvements find in all groups.
Table shows following percentage of improvements:
Group A - Mild improvement was found in 64% patients; moderate 
improvement was found in 36% patients (total number of patient n=25).
Group B - Mild improvement was found in 46.15% patients; moderate 
improvement was found in 53.85% patients (total number of 
patient n=13).
Group	C	-	Unchanged	4.55%	patient,	mild	improvement	was	found	in	
81.82% patients, moderate improvement was found in 13.64% patients 
(total number of patient n=22).
There is no marked improvement, or complete remission was found in 
any group.
In this study, the considerable effect was not achieved to some patients. 
This may be due to the short duration of the study. Charaka Samhita 
also described long-term of the treatment for the disease of Jirna and 
Atisthulata which was consider under Krichhrasadhya Vyadhi.
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